The North America Interventional Cardiology Devices Market would witness market growth of 6.7% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 17,753.9 thousand units, showcasing a growth of 6.5% (2019-2022).
Cardiovascular diseases, including coronary artery disease, heart failure, and arrhythmias, continue to cause morbidity and mortality. As the population ages and risk factors such as obesity and diabetes increase, the demand for interventional cardiology procedures and devices has grown. Continuous innovation in interventional cardiology devices has enabled more effective and safer treatments. This includes the development of advanced stents, drug-eluting stents, bioresorbable stents, and improved catheters and guidewires. These innovations enhance patient outcomes and reduce procedural complications.
The shift towards minimally invasive procedures has driven market growth. Patients and physicians prefer these approaches due to shorter recovery times, reduced hospital stays, and lower risks than traditional open-heart surgeries. Growing awareness of cardiovascular diseases and the importance of early detection and treatment has led to more patients seeking medical intervention. Patients are increasingly proactive about managing their heart health. Advances in genomics and biomarker research have paved the way for personalized treatment plans in cardiology. Tailoring interventions to individual patient characteristics are expected to drive growth in the market.
North American healthcare systems emphasize patient education and awareness of cardiovascular health. This has led to early diagnosis and intervention, driving the demand for interventional cardiology devices. North America is a prominent region for interventional cardiology devices, characterized by advanced healthcare infrastructure, clinical excellence, rigorous regulatory oversight, and a commitment to improving patient outcomes in cardiovascular care. The region continues to shape the global landscape of interventional cardiology through research, innovation, and best practices. Due to the above factors, North America's interventional cardiology devices market will increase significantly.
The US market dominated the North America Interventional Cardiology Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,521.4 million by 2030. The Canada market is experiencing a CAGR of 9.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 8.1% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers & Others. Based on Product, the market is segmented into Coronary Stents (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents), Accessory Devices (PTCA Guidewires, Diagnostic Catheters, PTCA Guiding Catheters, Introducer Sheaths), PTCA Balloon Catheters (Normal, Specialty, Drug Coated), Intravascular Imaging Catheters & Pressure Guidewires. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Interventional Cardiology Devices Market is Predict to reach $21.9 Billion by 2030, at a CAGR of 7.4%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, B. Braun Melsungen AG, Biotronik SE & Co. KG, Cardinal Health, Inc., Teleflex, Inc., Koninklijke Philips N.V., Alvimedica.
By End Use (Volume, Thousand Units, USD Million, 2019-2030)
By Product (Volume, Thousand Units, USD Million, 2019-2030)
By Country (Volume, Thousand Units, USD Million, 2019-2030)
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 